View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 31, 2016
Document and Entity Information [Abstract]
Trading Symbol	CCRN
Entity Registrant Name	CROSS COUNTRY HEALTHCARE INC
Entity Central Index Key	0001141103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		33,010,910

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 26,707	$ 2,453
Accounts receivable, net of allowances of $3,833 in 2016 and $4,045 in 2015	147,173	146,873
Prepaid expenses	5,271	4,521
Insurance recovery receivable	2,704	2,866
Other current assets	1,555	2,032
Total current assets	183,410	158,745
Property and equipment, net of accumulated depreciation of $42,191 in 2016 and $39,368 in 2015	12,434	10,470
Goodwill	77,376	95,096
Other intangible assets, net of accumulated amortization of $43,664 in 2016 and $39,754 in 2015	72,413	82,914
Debt issuance costs, net	981	376
Other non-current assets	18,122	17,994
Total assets	364,736	365,595
Current liabilities:
Accounts payable and accrued expenses	45,397	41,098
Accrued compensation and benefits	30,651	29,402
Current portion of long-term debt and capital lease obligations	2,272	8,071
Deferred purchase price	0	2,184
Other current liabilities	6,386	5,291
Total current liabilities	84,706	86,046
Long-term debt and capital lease obligations, less current portion	70,236	81,301
Non-current deferred tax liabilities	12,585	18,475
Long-term accrued claims	30,156	30,070
Contingent consideration	2,773	3,533
Other long-term liabilities	5,037	4,826
Total liabilities	205,493	224,251
Commitments and contingencies
Stockholders' equity:
Common stock	3	3
Additional paid-in capital	256,118	254,108
Accumulated other comprehensive loss	(1,219)	(1,207)
Accumulated deficit	(96,206)	(112,056)
Total Cross Country Healthcare stockholders' equity	158,696	140,848
Noncontrolling interest	547	496
Total stockholders' equity	159,243	141,344
Total liabilities and stockholders' equity	$ 364,736	$ 365,595

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 3,833	$ 4,045
Property and equipment, accumulated depreciation	42,191	39,368
Other intangible assets, accumulated amortization	42,279	38,419
Other Intangible Assets [Member]
Other intangible assets, accumulated amortization	$ 43,664	$ 39,754

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue from services	$ 214,988	$ 195,692	$ 611,014	$ 574,273
Operating expenses:
Direct operating expenses	156,778	144,206	446,912	427,387
Selling, general and administrative expenses	45,922	39,227	133,530	121,284
Bad debt expense	19	549	496	771
Depreciation	995	953	3,059	2,902
Amortization	1,097	982	3,910	2,947
Loss on sale of business	0	2,184	0	2,184
Acquisition-related contingent consideration	237	0	707	0
Acquisition and integration costs	0	584	0	742
Restructuring costs	611	140	611	1,147
Impairment charges	0	0	24,311	0
Total operating expenses	205,659	188,825	613,536	559,364
Income (loss) from operations	9,329	6,867	(2,522)	14,909
Other expenses (income):
Interest expense	1,435	1,654	4,678	5,163
(Gain) loss on derivative liability	(7,105)	2,894	(19,970)	385
Loss on early extinguishment of debt	0	0	1,568	0
Other income, net	(92)	(100)	(143)	(30)
Income before income taxes	15,091	2,419	11,345	9,391
Income tax expense (benefit)	802	(2,732)	(5,035)	(1,490)
Consolidated net income	14,289	5,151	16,380	10,881
Less: Net income attributable to noncontrolling interest in subsidiary	223	142	529	365
Net income attributable to common shareholders	$ 14,066	$ 5,009	$ 15,851	$ 10,516
Net income per share attributable to common shareholders - Basic
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ 0.44	$ 0.16	$ 0.49	$ 0.33
Net income (loss) per share attributable to common shareholders - Diluted
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.22	$ 0.16	$ (0.04)	$ 0.33
Weighted average common shares outstanding:
Basic (shares)	32,221	31,541	32,088	31,412
Diluted (shares)	36,255	32,168	36,215	32,048

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Consolidated net income	$ 14,289	$ 5,151	$ 16,380	$ 10,881
Other comprehensive income (loss), before income tax:
Unrealized foreign currency translation gain (loss)	15	(54)	(12)	(72)
Other comprehensive income (loss), before income taxes	15	(54)	(12)	(72)
Income tax (benefit) expense related to items of other comprehensive loss	0	0	0	0
Other comprehensive income (loss), net of tax	15	(54)	(12)	(72)
Comprehensive income	14,304	5,097	16,368	10,809
Less: Net income attributable to noncontrolling interest in subsidiary	223	142	529	365
Comprehensive income attributable to common shareholders	$ 14,081	$ 4,955	$ 15,839	$ 10,444

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Consolidated net income	$ 16,380	$ 10,881
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,969	5,849
Impairment charges	24,311	0
Amortization of debt discount and debt issuance costs	1,315	1,411
Provision for allowances	3,270	1,550
Loss on early extinguishment of debt	1,568	0
Deferred income tax benefit	(5,889)	(1,387)
(Gain) loss on derivative liability	(19,970)	385
Acquisition-related contingent consideration	662	0
Equity compensation	2,614	1,773
Loss on sale of business	0	2,184
Other non-cash costs	6	20
Changes in operating assets and liabilities:
Accounts receivable	(3,571)	(13,927)
Prepaid expenses and other assets	(1,036)	1,779
Income taxes	(476)	(407)
Accounts payable and accrued expenses	5,634	7,825
Other liabilities	482	930
Net cash provided by operating activities	32,269	18,866
Cash flows from investing activities
Proceeds from sale of business	500	7,500
Acquisition-related settlements - Medical Staffing Network	(2,155)	(123)
Acquisition-related settlements - Mediscan	297	0
Transaction costs related to sale of business	0	(338)
Purchases of property and equipment	(5,024)	(1,790)
Net cash (used in) provided by investing activities	(6,382)	5,249
Cash flows from financing activities
Proceeds from borrowing on Senior Credit Facility	40,000	0
Debt issuance costs	(1,182)	0
Principal payments on Second Lien Term Loan	(30,000)	0
Extinguishment fees	(641)	0
Repayments on Senior Secured Asset-Based revolving credit facility	(65,200)	(42,300)
Borrowings under Senior Secured Asset-Based revolving credit facility	57,200	38,800
Principal payment on Term Loan	(500)	0
Repayments of capital lease obligations	(60)	(80)
Cash paid for shares withheld for taxes	(603)	(543)
Payment of contingent consideration	(152)	0
Cash payments to noncontrolling shareholder	(478)	(353)
Net cash used in financing activities	(1,616)	(4,476)
Effect of exchange rate changes on cash	(17)	(50)
Change in cash and cash equivalents	24,254	19,589
Cash and cash equivalents at beginning of period	2,453	4,995
Cash and cash equivalents at end of period	$ 26,707	$ 24,584

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the "Company"). The condensed consolidated financial statements include all assets, liabilities, revenue, and expenses of InteliStaf of Oklahoma, LLC, which is controlled by the Company but not wholly-owned. The Company records the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2015 condensed consolidated balance sheet included herein was derived from the December 31, 2015 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K. Certain prior period amounts have been reclassified to conform to the current period presentation. See Note 12 - Segment Data.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, the valuation of accounts receivable, goodwill and intangible assets, other long-lived assets, share-based compensation, accruals for health, workers’ compensation and professional liability claims, valuation of deferred tax assets and the purchase price allocation, derivative liability, legal contingencies, future contingent considerations, income taxes and sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates. Restructuring Costs As of December 31, 2015, the balance in the accrued restructuring liability was $0.4 million, which was comprised of $0.1 million of post-employment benefits and $0.3 million of exit liabilities. During the three and nine months ended September 30, 2016, the Company incurred a restructuring charge of $0.6 million related to a cost savings initiative, which consisted of $0.4 million in post-employment benefits and $0.2 million of exit liabilities related to lease consolidations. During the three and nine months ended September 30, 2016, the Company paid $0.1 million and $0.3 million, respectively, relating to its restructuring liability. The payments made during the three months ended September 30, 2016 related to post-employment benefits, while the payments made during the nine months ended September 30, 2016 related to $0.2 million in post-employment benefits and $0.1 million in exit liabilities. As of September 30, 2016, the balance in the accrued restructuring liability was $0.7 million, which was comprised of $0.3 million of post-employment benefits and $0.4 million of exit liabilities. Recently Adopted Accounting Pronouncement In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Prior to the issuance of the ASU, entities were required to retrospectively apply adjustments made to provisional amounts recognized in a business combination. The Company adopted this guidance in the first quarter of 2016, with no impact on its financial position and results of operations upon adoption. This new guidance may impact the Company for potential measurement adjustments related to its 2015 acquisition. See Note 3 - Acquisitions. In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40), Customers Accounting for Fees Paid in a Cloud Computing Arrangement, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license element, then the customer should account for the software license element arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company prospectively adopted this guidance in the first quarter of 2016, with no impact on its condensed consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs. This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The Company adopted this guidance in the first quarter of 2016, and reclassified $0.5 million of the Company's net debt issuance costs to long-term debt and capital lease obligations in its condensed consolidated balance sheets as of September 30, 2016 and December 31, 2015.

ACQUISITIONS

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

ACQUISITIONS

Mediscan

On October 30, 2015, the Company completed the acquisition of all of the membership interests of New Mediscan II, LLC, Mediscan Diagnostic Services, LLC, and Mediscan Nursing Staffing, LLC (collectively "Mediscan") for a purchase price of $29.9 million in cash ($28.0 million plus working capital estimate) and $4.7 million in shares (or 349,871 shares) of the Company's Common Stock, subject to a net working capital adjustment. In the first quarter of 2016, the net working capital adjustment was settled consistent with the receivable balance as of December 31, 2015.

The sellers are also eligible to receive an earnout based on Mediscan's 2016 and 2017 performance that could provide up to an additional $7.0 million of cash. In connection with the Mediscan acquisition, the Company assumed additional contingent purchase price liabilities for a previously acquired business that are payable annually based on specific performance criteria for the 2016 through 2019 years. As of September 30, 2016, a total of $4.2 million was estimated for the fair value of these contingent consideration payments and accordingly, is included in other current liabilities and contingent consideration on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements. The shares of Common Stock issued in connection with the acquisition were subject to a lockup period, which ended April 30, 2016.

The acquisition has been accounted for in accordance with FASB ASC 805, Business Combinations, using the acquisition method of accounting. Mediscan's results of operations are included in the consolidated statements of operations from October 30, 2015 and have been included in the Company's Nurse and Allied Staffing business segment. As such, the associated goodwill related to the acquisition is fully allocated to Nurse and Allied Staffing.

Medical Staffing Network

On June 30, 2014, the Company acquired substantially all of the assets and certain liabilities of Medical Staffing Network Healthcare, LLC ("MSN"). Of the purchase price, $2.5 million was deferred and due to the seller 21 months from the acquisition date, less any COBRA expenses incurred by the Company on behalf of former MSN employees over that period. The Company incurred $0.4 million in COBRA expenses since the MSN acquisition and, on April 1, 2016, released to the seller the remaining liability of $2.1 million.

Pro Forma Financial Information

The following unaudited pro forma financial information approximates the consolidated results of operations of the Company as if the Mediscan acquisition had occurred as of January 1, 2015, after giving effect to certain adjustments, including additional interest expense on the amount the Company borrowed on the date of the transaction, the amortization of acquired intangible assets, and the elimination of certain expenses that will not be recurring in post-acquisition periods, net of an estimated income tax impact. These results are not necessarily indicative of future results as they do not include incremental investments in support functions, elimination of costs for integration or operating synergies or an estimate of any impact on interest expense resulting from the operating cash flow of the acquired business, among other adjustments that could be made in the future but are not factually supportable on the date of the transaction.



	Nine Months Ended
	September 30, 2015
	(unaudited, amounts in thousands)

Revenue from services	$	603,495

Net income attributable to common shareholders	$	11,964

Net income per share attributable to common shareholders - Basic	$	0.38

Net income per share attributable to common shareholders - Diluted	$	0.37

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

DISPOSAL DISPOSAL	9 Months Ended
DISPOSAL DISPOSAL	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
DISPOSAL	DISPOSAL Cross Country Education On July 21, 2015, the Company's Board of Directors approved an agreement to sell the Company's education seminars business, Cross Country Education, LLC ("CCE"). CCE provided in-person seminars to healthcare professionals and was non-core to the Company’s business. The Company used the net proceeds from the transaction to finance the Mediscan acquisition in the fourth quarter of 2015. Since the disposal of the education seminars business did not represent a strategic shift that would have a major effect on the Company’s operations and financial results, it was not reflected as discontinued operations. On July 27, 2015, the Company entered into an Agreement and Plan of Merger to sell its wholly-owned subsidiary, CCE, to a third party ("Buyer"). On August 31, 2015, the Company completed the sale of CCE to the Buyer. The Company received $8.0 million in cash, subject to a net working capital adjustment, of which $0.5 million was held in escrow for a period of 12 months following the closing to provide partial security to Buyer in the event of any breach of the representations, warranties and covenants of the Company. In September 2016, the full amount of escrow, which had been reflected as an escrow receivable, was released to the Company. The purchase price also included an earnout of up to $0.5 million related to the performance of CCE for the year ended December 31, 2015, which was not made. See Note 10 - Fair Value Measurements. The operating results of CCE were included in the Other Human Capital Management Services segment. See Note 12 - Segment Data for further information. The Company recognized a pre-tax loss of $2.2 million related to the sale of the business, which is included in income (loss) from operations in its condensed consolidated statements of operations for the three and nine months ended September 30, 2015.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

COMPREHENSIVE INCOME (LOSS)	9 Months Ended
COMPREHENSIVE INCOME (LOSS)	Sep. 30, 2016
Equity [Abstract]
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS) Total comprehensive income (loss) includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes. Certain of the Company’s foreign subsidiaries use their respective local currency as their functional currency. In accordance with the Foreign Currency Matters Topic of the FASB ASC, assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was approximately $1.2 million at both September 30, 2016 and December 31, 2015. There was no income tax impact related to foreign currency translation adjustments for the three and nine month periods ended September 30, 2016 and September 30, 2015.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016			2015		2016			2015
	(amounts in thousands, except per share data)
Numerator:
Net income attributable to common shareholders - Basic	$	14,066		$	5,009	$	15,851		$	10,516
Interest on Convertible Notes	853			*		2,529			*
Gain on derivative liability	(7,105		)	*		(19,970		)	*
Net income (loss) attributable to common shareholders - Diluted	$	7,814		$	5,009	$	(1,590	)	$	10,516

Denominator:
Weighted average common shares - Basic	32,221			31,541		32,088			31,412
Effective of dilutive shares:
Share-based awards	513			627		606			636
Convertible Notes	3,521			—		3,521			—
Weighted average common shares - Diluted	36,255			32,168		36,215			32,048

Net income per share attributable to common shareholders - Basic	$	0.44		$	0.16	$	0.49		$	0.33

Net income (loss) per share attributable to common shareholders - Diluted	$	0.22		$	0.16	$	(0.04	)	$	0.33

* For the three and nine months ended September 30, 2015, the Convertible Notes would have been anti-dilutive if converted at the beginning of the respective periods and therefore, amounts are not applicable.

For the periods presented, no tax benefits have been assumed in the weighted average share calculation due to a full valuation allowance on the Company's deferred tax assets.

The following table represents the securities that could potentially dilute net income per share attributable to common shareholders in the future that were not included in the computation of diluted net income per share attributable to common shareholders because to do so would have been anti-dilutive for the periods presented:



	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2016	2015	2016	2015
	(amounts in thousands)

Convertible Notes and share-based awards	2	3,521	13	3,521

GOODWILL AND OTHER INTANGIBLES

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

As of September 30, 2016 and December 31, 2015, the Company had the following acquired intangible assets:



	September 30, 2016						December 31, 2015
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(amounts in thousands)
Intangible assets subject to amortization:
Databases	$	31,225	$	15,646	$	15,579	$	31,225	$	14,150	$	17,075
Customer relationships	41,212		22,848		18,364		47,204		20,734		26,470
Non-compete agreements	3,603		3,516		87		3,603		3,486		117
Trade names, definite-lived	3,200		269		2,931		3,200		49		3,151
	$	79,240	$	42,279	$	36,961	$	85,232	$	38,419	$	46,813

Intangible assets not subject to amortization:
Goodwill					$	77,376					$	95,096
Trade names					35,452						36,101
					$	112,828					$	131,197

As of September 30, 2016, estimated annual amortization expense is as follows:



Through Year Ending December 31:	(amounts in thousands)
2016	$	1,040
2017	4,140
2018	4,055
2019	4,019
2020	3,914
Thereafter	19,793
	$	36,961

The changes in the carrying amount of goodwill by segment are as follows:



	Nurse And Allied Staffing			Physician Staffing			Other Human Capital Management Services			Total
	(amounts in thousands)
Balances as of December 31, 2015
Aggregate goodwill acquired	$	302,005		$	43,405		$	19,307		$	364,717
Sale of CCE	—			—			(9,889		)	(9,889		)
Accumulated impairment loss	(259,732		)	—			—			(259,732		)
Goodwill, net of impairment loss	42,273			43,405			9,418			95,096

Changes to aggregate goodwill in 2016
Impairment charges	—			(17,720		)	—			(17,720		)

Balances as of September 30, 2016
Aggregate goodwill acquired	302,005			43,405			19,307			364,717
Sale of CCE	—			—			(9,889		)	(9,889		)
Accumulated impairment loss	(259,732		)	(17,720		)	—			(277,452		)
Goodwill, net of impairment loss	$	42,273		$	25,685		$	9,418		$	77,376

During the three months ended June 30, 2016 and nine months ended September 30, 2016, total impairment charges on the condensed consolidated statement of operations were $24.3 million and entirely related to the Physician Staffing reporting unit. The impairment charges in the second quarter of 2016 included $17.7 million related to goodwill, $0.6 million related to trade names, and $6.0 million related to customer relationships. In the second quarter of 2016, the Physician Staffing reporting unit continued to under-perform relative to management’s expectations. The lower than expected revenue was driven by lower booking volumes partly due to the loss of customers, and margins that were negatively impacted from continued investments in the business all through the first half of 2016. The Company considered these factors to be impairment indicators that warranted impairment testing of goodwill and other intangible assets as described below. There were no such indicators of impairment noted during the three months ended September 30, 2016.

Second Quarter 2016 Goodwill Impairment

During the second quarter of 2016, in order to determine the fair value of the Physician Staffing reporting unit, the Company used a combination of an income and a market approach to calculate the fair value of the Physician Staffing reporting unit. The discounted cash flow that served as the primary basis for the income approach was based on the Company’s discrete financial forecast of revenue, gross profit margins, operating costs and cash flows. It also considered historical and estimated future results, general economic and market conditions, as well as the impact of planned business and operational strategies. The assumptions used in the income approach included a discount rate of 11.5% and a terminal value growth rate of 3.0% for cash flows beyond the discrete forecast period of ten years.

Assumptions used in the market approach included valuation multiples based on an analysis of multiples for comparable public companies. The Company utilized total enterprise value/Earnings before Interest Taxes Depreciation and Amortization (EBITDA) ranging from 7.5 to 8.5.

A 50% weighting was applied to the components of each approach to estimate the total fair value of goodwill. This weight is an estimate by management and was developed based on the specific characteristics, risks and uncertainties of the Physician Staffing reporting unit.

As a result of the testing, the Company compared the implied fair value of goodwill to its carrying amount and recorded a non-cash pre tax goodwill impairment charge of $17.7 million.

Second Quarter 2016 Other Intangible Asset Impairment

Trade Names

The Company valued the Physician Staffing trade names based on a Relief From Royalty methodology using projected cash flows of an estimated royalty fee. The royalty rate was determined by a blended rate using the Market Royalty Rate Method and the Apportionment of Profit Method. The calculated value of the trade names was compared to its carrying amount and, as a result, the Company recorded a non-cash pre tax impairment charge of $0.6 million.

Customer Relationships

The Company valued the Physician Staffing customer relationships based on the Multi-Period Excess Earnings Method (MPEEM). The MPEEM estimates the fair value based on the present value of the allocated future economic benefits. The inputs include the projected revenue and associated expenses from the customers, an estimated attrition rate, and a discount rate of 13.5%. The Company performed a recoverability test on the asset group which customers are a part of and deemed customer relationships to be impaired. As a result, the calculated value of customer relationships was compared to its carrying amount and the Company recorded a non-cash pre tax impairment charge of $6.0 million.

The Company based its fair value estimates on assumptions it believed to be reasonable, but such assumptions are subject to inherent uncertainty. Actual results may differ from those estimates.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

DEBT

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

DEBT

At September 30, 2016 and December 31, 2015, long-term debt consists of the following:



	September 30, 2016						December 31, 2015
	Principal			Unamortized Discount and Debt Issuance Costs			Principal			Unamortized Discount and Debt Issuance Costs
	(amounts in thousands)
Term Loan, interest 2.77%	$	39,500		$	(388	)	$	—		$	—
Senior Secured Asset-Based, weighted average interest 2.41%	—			—			8,000			—
Second Lien Term Loan, interest 5.75%	—			—			30,000			(1,052		)
Convertible Notes, fixed rate interest of 8.00%	25,000			(5,005		)	25,000			(6,007		)
Convertible Notes derivative liability	13,367			—			33,337			—
Capital lease obligations	34			—			94			—
Total debt	77,901			(5,393		)	96,431			(7,059		)
Less current portion	(2,272		)	—			(8,071		)	—
Long-term debt	$	75,629		$	(5,393	)	$	88,360		$	(7,059	)

As of September 30, 2016, the aggregate scheduled maturities of debt are as follows:



	Term Loan		Convertible Notes		Capital Leases
	(amounts in thousands)
Through Years Ending December 31:
2016	$	500	$	—	$	11
2017	2,500		—		13
2018	3,000		—		8
2019	3,500		—		2
2020	4,000		25,000		—
Thereafter	26,000		—		—
Total	$	39,500	$	25,000	$	34

At December 31, 2015, the Company had a senior secured asset-based revolving credit facility ("First Lien Loan"), with a termination date of June 30, 2017, in the aggregate principal amount of up to $85.0 million, which included a subfacility for swingline loans up to an amount equal to 10% of the aggregate Revolver Commitments, as defined in the agreement, and a $35.0 million subfacility for standby letters of credit. The Company also had a five-year second lien term loan facility ("Second Lien Term Loan") in an aggregate principal amount of $30.0 million. The Company had the ability, at its option at any time, to prepay the Second Lien Term Loan in whole or in part at the redemption prices set forth therein, which ranged from 103% of the principal amount thereof for prepayments during the period July 1, 2015 through June 30, 2016, 102% of the principal amount thereof for prepayments during the period July 1, 2016 through June 30, 2017, and 100% of the principal amount thereof for prepayments after June 30, 2017.

2016 Senior Credit Facilities

On June 22, 2016, the Company entered into a senior credit agreement (“Credit Agreement”), which provides a term loan of $40.0 million ("Term Loan") and a revolving credit facility of up to $100.0 million ("Revolving Credit Facility") (together with the Term Loan, the "Senior Credit Facilities") both of which mature in five years. The Revolving Credit Facility includes a subfacility for swingline loans up to an amount not to exceed $15.0 million, and a $35.0 million sublimit for the issuance of standby letters of credit. The Credit Agreement also includes a provision permitting the Company, subject to certain conditions, to increase the aggregate amount of the commitments under the Revolving Credit Facility or establish one or more additional term loans in an aggregate amount of up to $50.0 million with optional additional commitments from existing lenders or new commitments from additional lenders. The Term Loan is payable in quarterly installments, with the first payment made September 30, 2016, and each such installment being in the aggregate principal amount (subject to adjustment as a result of prepayments) equal to 1.25% of the principal amount for the first four installments, 1.875% for the next eight installments and 2.50% of the principal amount for the remaining installments.

Proceeds of the Senior Credit Facilities were used primarily to refinance the Company’s First Lien Loan and Second Lien Term Loan and to pay related transaction fees and expenses, including a prepayment penalty of $0.6 million. In addition, as of June 22, 2016, $23.1 million of standby letters of credit issued under the First Lien Loan have been rolled into and been deemed issued under the Revolving Credit Facility. The Revolving Credit Facility can be used to provide ongoing working capital, fund permitted acquisitions and for other general corporate purposes of the Company and its subsidiaries.

The repayment of the Second Lien Term Loan was treated as extinguishment of debt and, as a result, the Company recognized a loss on extinguishment of debt of approximately $1.6 million in the second quarter of 2016, related to the write-off of unamortized net debt discount and issuance costs as well as transaction fees and expenses.

Subject to the Credit Agreement, the Company pays interest on (i) each Base Rate Loan at the Base Rate (as defined therein) plus the Applicable Margin in effect from time to time, (ii) each LIBOR Index Rate Loan at the One Month LIBOR Index Rate (as defined therein) plus the Applicable Margin in effect from time to time and (iii) each Eurodollar Loan at the Adjusted LIBOR for the applicable Interest Period (as defined therein) in effect for such Loan plus the Applicable Margin in effect from time to time. The Applicable Margin, as of any date, is a percentage per annum determined by reference to the applicable Consolidated Net Leverage Ratio (as defined by the agreement) in effect on such date as set forth in the table below.



Level	Consolidated Net Leverage Ratio	Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee	Base Rate Loans	Commitment Fee
I	Less than 1.50:1.00	1.75%	0.75%	0.25%
II	Greater than or equal to 1.50:1.00 but less than 2.00:1.00	2.00%	1.00%	0.30%
III	Greater than or equal to 2.00:1.00 but less than 2.50:1.00	2.25%	1.25%	0.30%
IV	Greater than or equal to 2.50:1.00 but less than 3.00:1.00	2.50%	1.50%	0.35%
V	Greater than or equal to 3.00:1.00	2.75%	1.75%	0.40%

As of September 30, 2016, the Term Loan and Revolving Credit Facility bore interest at a rate equal to One Month LIBOR plus 225 basis points. The interest rate is subject to an increase of 200 basis points if an event of default exists under the Credit Agreement. The Company is required to pay a commitment fee on the average daily unused portion of the Revolving Credit Facility, based on the Applicable Margin which was 0.30% as of September 30, 2016.

The Company has the right at any time and from time to time to prepay any borrowing, in whole or in part, without premium or penalty, by giving irrevocable written notice (or telephonic notice promptly confirmed in writing) except that such notice shall be revocable if a prepayment is being made in anticipation of concluding a financing arrangement, and the Company is ultimately unable to secure such financing arrangement. The Company is required to prepay the Senior Credit Facilities under certain circumstances including from net cash proceeds from asset sales or dispositions in excess of certain thresholds, as well as from net cash proceeds from the issuance of certain debt by the Company.

The Credit Agreement contains customary representations, warranties, and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to some exceptions, on (i) indebtedness and preferred equity, (ii) liens, (iii) fundamental changes, (iv) investments, (v) restricted payments, and (vi) sale of assets and certain other restrictive agreements. The Credit Agreement also contains customary events of default, such as payment defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency, the occurrence of a defined change in control and the failure to observe the negative covenants and other covenants related to the operation of the Company’s business. The Credit Agreement also includes two financial covenants, commencing with the fiscal quarter ending September 30, 2016: (i) limiting a maximum Consolidated Total Leverage ratio (as defined therein) to be no greater than 3.50:1.00 for the fiscal quarters ending September 30, 2016 through June 30, 2017, 3.25:1.00 for the fiscal quarters ending September 30, 2017 through June 30, 2018, and 3.00:1.00 for each fiscal quarter ending thereafter and as adjusted pursuant to a Qualified Permitted Acquisition (as defined therein); and (ii) requiring a minimum Consolidated Fixed Charge Coverage ratio (as defined therein) as of the end of each fiscal quarter of 1.50:1.00. As of September 30, 2016, the Company was in compliance with the financial covenants and other covenants contained in the Credit Agreement.

The obligations under the Credit Agreement are guaranteed by all of the Company’s domestic wholly-owned subsidiaries. The obligations under the Credit Agreement are secured by a first-priority security interest in the Collateral (as defined therein).

As of September 30, 2016, the Company had $22.2 million letters of credit outstanding and $77.8 million available under the Revolving Credit Facility. The letters of credit relate to the Company’s workers’ compensation and professional liability insurance policies.

Convertible Notes

As of September 30, 2016, the Convertible Notes are convertible at the option of the holders thereof at any time into shares of the Company’s common stock, par value $0.0001 per share (Common Stock), at an initial conversion price of $7.10 per share, or 3,521,126 shares of Common Stock. After three years from the issuance date, the Company has the right to force a conversion of the Convertible Notes if the volume-weighted average price (VWAP) per share of its Common Stock exceeds 125% of the then conversion price for 20 days of a 30 day trading period. The conversion price is subject to adjustment pursuant to customary weighted average anti-dilution provisions including adjustments for the following: Common Stock dividends or distributions; issuance of any rights, warrants of options to acquire Common Stock; distributions of property; tender offer or exchange offer payments; cash dividends; or certain issuances of Common Stock at less than the conversion price. Upon conversion of the Convertible Notes, the Company will exchange, for the applicable conversion amount thereof a number of shares of Common Stock equal to the amount determined by dividing (i) such conversion amount by (ii) the conversion price in effect at the time of conversion provided that the number of shares of Common Stock issued upon conversion, when aggregated with the aggregate number of shares of Common Stock previously issued upon conversion cannot exceed 6,420,028 shares of Common Stock. If this share cap results in the issuance of fewer shares of Common Stock, the Company will pay to the holders of the Convertible Notes an amount in cash equal to the product of (i) the number of shares not delivered as a result of the cap and (ii) the 30-day VWAP as of the close of business on the Business Day immediately preceding the conversion date. No fractional shares of Common Stock will be issued upon conversion of the Conversion Notes. In lieu of fractional shares, the Company shall pay cash in respect of each fractional share multiplied by the 30-day VWAP as of the closing of business on the Business Day immediately preceding the conversion date as well as any unpaid accrued interest.

The Convertible Notes bear interest at a rate of 8.00% per annum, payable in quarterly cash installments; provided, however, that, at the Company’s option, up to 4.00% of the interest payable may be “paid-in-kind” through a quarterly addition of such “paid-in-kind” interest amount to the principal amount of the Convertible Notes. The Convertible Notes will mature on June 30, 2020, unless earlier repurchased, redeemed or converted. Subject to certain exceptions, the Company is not permitted to redeem the Convertible Notes until June 30, 2017. If the Company redeems the Convertible Notes on or after June 30, 2017, the Company is required to pay a premium of 15% of the amount of principal of the Convertible Notes redeemed.

If the Convertible Notes are redeemed prior to June 30, 2017, pursuant to a Prohibited Transaction, as defined by the agreement, the Company is required to pay a premium equal to the greater of (i) the sum of (a) the amount of principal of the Convertible Notes redeemed, plus (b) the accrued but unpaid interests on the principal amount so redeemed to the date of the redemption, plus (c) a “make whole” amount (described below) and (ii) the sum of (x) the average 30-day VWAP per share of Common Stock multiplied by the number of shares of Common Stock that the redeemed Convertible Notes are then convertible into, with no maximum, and (y) the accrued but unpaid interest on the Convertible Notes. The “make whole” amount is equal to the excess, if any, of (1) the present value at the date of redemption of (A) 115% of the principal amount of the Convertible Notes redeemed, plus (B) all remaining scheduled interest due on the principal amount of the notes being redeemed through June 30, 2017 computed using a discount rate equal to the Treasury rate as of the date of redemption plus 50 basis points over (2) the outstanding principal amount of the Convertible Notes then redeemed.

CONVERTIBLE NOTES DERIVATIVE LIABILITY

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

CONVERTIBLE NOTES DERIVATIVE LIABILITY

Derivative financial instruments, as defined in ASC 815, Accounting for Derivative Financial Instruments and Hedging Activities, consist of financial instruments or other contracts that contain a notional amount and one or more underlyings (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets.

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company issued Convertible Notes with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in the financial statements.

The Convertible Notes are subject to anti-dilution adjustments that allow for the reduction in the Conversion Price, as defined in the agreement, in the event the Company subsequently issues equity securities including Common Stock or any security convertible or exchangeable for shares of Common Stock for a price less than the current conversion price. In addition, the Convertible Notes allow the issuer to exercise optional redemption features and the holder to exercise an offer to purchase feature, under certain conditions. The Company accounted for the conversion option in accordance with ASC 815. Since this conversion feature is not considered to be solely indexed to the Company’s own stock the derivative was recorded as a liability in the line item long-term debt on the Company's condensed consolidated balance sheets. See Note 8 - Debt.

The Company’s Convertible Notes derivative liability is measured at fair value using a trinomial lattice model. The optional redemption features, along with the offer to purchase features are incorporated into the valuation model. Inputs into the model require estimates, including such items as estimated volatility of the Company's stock, estimated credit risk of the Company, estimated probabilities of change of control and issuance of additional financing, risk-free interest rate, and the estimated life of the financial instruments being fair valued. In addition, since the conversion price contains an anti-dilution adjustment, the probability that the Conversion Price of the Notes would decrease as the share price decreased is incorporated into the valuation calculation.

The inputs into the valuation model are as follows:



	September 30, 2016
Closing share price	$11.78
Conversion price	$7.10
Risk-free rate	0.91%
Expected volatility	40%
Dividend yield	—%
Expected life	3.75

The fair value of this derivative liability is primarily determined by fluctuations in our stock price. In addition, changes in our credit risk profile impact the fair value determination. As of September 30, 2016, a $1 increase or decrease in our stock price would result in a corresponding increase or decrease of approximately $3.3 million in the fair value of the derivative liability, and a 1% increase or decrease in interest rates would result in a corresponding increase or decrease of $0.8 million in the fair value of the derivative liability. These fluctuations result in a current period gain or loss that is presented on the condensed consolidated statements of operations as (gain) loss on derivative liability.

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

The Fair Value Measurements and Disclosures Topic of the FASB ASC defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Fair Value Measurements and Disclosures Topic also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Items Measured at Fair Value on a Recurring Basis

At September 30, 2016 and December 31, 2015, the Company’s financial assets/liabilities required to be measured on a recurring basis were: contingent consideration receivable, deferred compensation liability included in other long-term liabilities, convertible notes derivative liability included in long-term debt and capital lease obligations, and contingent purchase price liabilities included in deferred purchase price on the condensed consolidated balance sheets.

Contingent consideration receivable—In connection with the sale of its education seminars business, Cross Country Education, LLC ("CCE"), the Company treated a related performance-based earnout as a contingent consideration receivable at December 31, 2015 for accounting purposes. The Company assigned no fair value to this earnout as of December 31, 2015 as the performance milestones were not met. The amount escrowed for this earnout was released to the buyer in the first quarter of 2016.

Deferred compensation—The Company utilizes Level 1 inputs to value its deferred compensation liability. The Company’s deferred compensation liability is measured using publicly available indices that define the liability amounts, as per the plan documents.

Convertible Notes derivative liability—The Company utilizes Level 3 inputs to value its convertible notes derivative liability. See Note 9 - Convertible Notes Derivative Liability.

Contingent purchase price liabilities—Potential earnout payments related to the acquisition of Mediscan are contingent upon meeting certain performance requirements through 2019. See Note 3 - Acquisitions. The long-term portion of these liabilities is included in contingent consideration, and the short-term portion is included in other current liabilities on the condensed consolidated balance sheets. The Company utilized Level 3 inputs to value these contingent purchase price liabilities as significant unobservable inputs were used in the calculation of their fair value. Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model in a Monte Carlo simulation setting, utilizing significant unobservable inputs, including the expected volatility of Mediscan gross profits and an estimated discount rate commensurate with the risks of the expected gross profit stream. Significant increases (decreases) in the volatility, or decreases (increases) in the discount rate would result in a significantly higher (lower) fair value, respectively, and commensurate changes to these liabilities. The fair value of contingent consideration and the associated liabilities will be adjusted to fair value at each reporting date until actual settlement occurs, with the changes in fair value and liability accretion reflected as acquisition-related contingent consideration on the condensed consolidated statements of operations.

The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis as of September 30, 2016 and December 31, 2015:

Fair Value Measurements



	September 30, 2016		December 31, 2015
Financial Liabilities:	(amounts in thousands)
(Level 1)
Deferred compensation	$	1,435	$	1,412
(Level 3)
Convertible Notes derivative liability	$	13,367	$	33,337
Contingent purchase price liabilities	$	4,196	$	3,686

The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy:



	Contingent Purchase			Convertible Notes
	Price Liabilities (a)			Derivative Liability
	(amounts in thousands)
December 31, 2015	$	3,686		$	33,337
Payments	(17		)	—
Accretion expense	287			—
Valuation gain for the period	—			(16,436		)
March 31, 2016	3,956			16,901
Accretion expense	183			—
Valuation loss for the period	—			3,571
June 30, 2016	4,139			20,472
Payments	(135		)	—
Accretion expense	192			—
Valuation gain for the period	—			(7,105		)
September 30, 2016	$	4,196		$	13,367

_______________

(a)

Related to the Mediscan acquisition on October 30, 2015. See Note 3 - Acquisitions. The key assumptions used to calculate the fair value of contingent consideration at the acquisition date remained consistent at September 30, 2016. Accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statement of operations. Should the assumptions regarding probability of achievement of certain targets change in future periods, the change in fair value of the contingent consideration will be recognized, along with accretion expense, as acquisition-related contingent consideration.

Items Measured at Fair Value on a Non-Recurring Basis

Goodwill, trade names, and other identifiable intangible assets are reviewed for impairment annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If the testing performed indicates that impairment has occurred, the Company records a non-cash impairment charge for the difference between the carrying amount of the goodwill or other intangible assets and the implied fair value of the goodwill or other intangible assets in the period the determination is made. See Note 7 - Goodwill and Other Intangibles.

Other Fair Value Disclosures

Financial instruments not measured or recorded at fair value in the accompanying condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and short and long-term debt. The estimated fair value of accounts receivable, accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments. The estimated fair value of the Company's debt was calculated using a discounted cash flow analysis and appropriate valuation methodologies using Level 2 inputs from available market information. The estimated fair value of the Company's new term loan facility approximates principal amount due to the short time span since the Company entered into the new Credit Agreement.

The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value:



	September 30, 2016				December 31, 2015
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Financial Liabilities:			(amounts in thousands)
(Level 2)
Second Lien Term Loan, net	$	—	$	—	$	28,948	$	30,600
Term Loan, net	$	39,112	$	39,500	$	—	$	—
Convertible Notes, net	$	19,995	$	28,750	$	18,993	$	23,250
Senior Secured Asset-Based Loan	$	—	$	—	$	8,000	$	8,000

Concentration of Risk

The Company has invested its excess cash in highly-rated overnight funds and other highly-rated liquid accounts. The Company has been exposed to credit risk associated with these investments. The Company minimizes its credit risk relating to these positions by monitoring the financial condition of the financial institutions involved and by primarily conducting business with large, well established financial institutions and diversifying its counterparties.

The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts represents the Company’s estimate of uncollectible receivables based on a review of specific accounts and the Company’s historical collection experience. The Company writes off specific accounts based on an ongoing review of collectability as well as past experience with the customer. The Company’s contract terms typically require payment between 15 to 60 days from the date services are provided and are considered past due based on the particular negotiated contract terms. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Stock Repurchase Program

During the nine months ended September 30, 2016 and 2015, the Company did not repurchase any shares of its Common Stock under its February 2008 Board authorization.

As of September 30, 2016, the Company may purchase up to an additional 942,443 shares of Common Stock under the February 2008 Board authorization, subject to certain conditions in the Company's new Credit Agreement. The Company may repurchase up to an aggregate amount not to exceed $2.5 million in any fiscal year, or an unlimited amount if the Company meets certain conditions as described in its new Credit Agreement. At September 30, 2016, the Company had 32,238,463 shares of Common Stock outstanding.

Share-Based Payments

During the nine months ended September 30, 2016, 246,020 of restricted stock awards and 202,442 of performance stock awards were granted under the 2014 Omnibus Incentive Plan (2014 Plan) to the Company's non-employee Directors and management team. Pursuant to the 2014 Plan, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. If the minimum level of performance is attained for the 2016 awards, restricted stock will be issued with a vesting date of December 31, 2018, subject to the employee’s continuing employment.

During the first quarter of 2016, the Company's Compensation Committee of the Board of Directors approved a 100% level of attainment for the 2015 performance-based share awards, resulting in the issuance of 148,178 performance shares that will vest on December 31, 2017.

The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the nine months ended September 30, 2016:



	Restricted Stock Awards				Performance Stock Awards
	Number of Shares		Weighted Average Grant Date Fair Value		Number of Target Shares		Weighted Average Grant Date Fair Value
Unvested restricted stock awards, January 1, 2016	586,488		$	7.82	234,138		$	9.81
Granted	246,020		$	12.01	202,442		$	11.63
Vested	(272,597	)	$	7.06	—		$	—
Forfeited	(14,000	)	$	10.93	(10,667	)	$	11.77
Unvested restricted stock awards, September 30, 2016	545,911		$	10.01	425,913		$	10.62

During the three and nine months ended September 30, 2016, $0.8 million and $2.6 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 9,742 and 225,107 shares, respectively, of Common Stock were issued upon the vesting of restricted stock.

During the three and nine months ended September 30, 2015, $0.6 million and $1.8 million, respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 10,330 and 190,631 shares, respectively, of Common Stock were issued upon the vesting of restricted stock.

SEGMENT DATA

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

SEGMENT DATA

In accordance with the Segment Reporting Topic of the FASB ASC, the Company reports three business segments – Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. The Company manages and segments its business based on the services it offers to its customers as described below:

●

Nurse and Allied Staffing – Nurse and Allied Staffing provides traditional staffing, including temporary and permanent placement of travel nurses and allied professionals and branch-based local nurses and allied staffing. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, retailers, and many other healthcare providers throughout the U.S. The results of the Mediscan acquisition have been aggregated with the Company's Nurse and Allied Staffing business segment. See Note 3 - Acquisitions.

●

Physician Staffing – Physician Staffing provides physicians in many specialties, certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) as independent contractors on temporary assignments throughout the U.S. at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.


●	Other Human Capital Management Services – Subsequent to the sale of CCE on August 31, 2015, Other Human Capital Management Services includes retained and contingent search services for physicians, healthcare executives and other healthcare professionals within the U.S.

The Company’s management evaluates performance of each segment primarily based on revenue and contribution income. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments’ internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments.

Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows:



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016			2015		2016			2015
	(amounts in thousands)
Revenues:
Nurse and Allied Staffing	$	186,623		$	157,338	$	527,436		$	459,127
Physician Staffing	25,090			30,959		73,470			88,100
Other Human Capital Management Services	3,275			7,395		10,108			27,046
	$	214,988		$	195,692	$	611,014		$	574,273

Contribution income: (a)
Nurse and Allied Staffing (b)	$	19,472		$	16,560	$	53,877		$	40,283
Physician Staffing	2,400			3,197		6,003			7,541
Other Human Capital Management Services	(154		)	372		(196		)	1,721
	21,718			20,129		59,684			49,545

Unallocated corporate overhead (b)	9,449			8,419		29,608			24,714
Depreciation	995			953		3,059			2,902
Amortization	1,097			982		3,910			2,947
Loss on sale of business	—			2,184		—			2,184
Acquisition and integration costs	—			584		—			742
Acquisition-related contingent consideration	237			—		707			—
Restructuring costs	611			140		611			1,147
Impairment charges	—			—		24,311			—
Income (loss) from operations	$	9,329		$	6,867	$	(2,522	)	$	14,909

_______________

(a)

The Company defines contribution income as income or loss from operations before depreciation, amortization, loss on sale of business, acquisition and integration costs, acquisition-related contingent consideration, restructuring costs, impairment charges and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance and is provided in accordance with ASC 280, Segment Reporting Topic of the FASB ASC.


(b)	For the three and nine months ended September 30, 2015, $0.3 million and $0.9 million, respectively, of expenses were reclassified from Nurse and Allied Staffing to unallocated corporate overhead to conform to the current period presentation.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Commitments

The Company has entered into non-cancelable operating lease agreements for the rental of office space and equipment. Certain of these leases include options to renew as well as rent escalation clauses and in certain cases, incentives from the landlord for rent-free months and premises reductions, and allowances for tenant improvements. The rent escalations and incentives have been reflected in the table below.

Future minimum lease payments, as of September 30, 2016, associated with these agreements with terms of one year or more are as follows:



Through Year Ending December 31:	(amounts in thousands)
2016	$	1,900
2017	6,857
2018	5,851
2019	4,349
2020	3,834
Thereafter	16,605
	$	39,396

Legal Contingencies

The Company is subject to legal proceedings and claims that arise in the ordinary course of its business. The Company does not believe the outcome of these matters will have a material adverse effect on the Company's business, financial condition, results of operations or cash flows.

Sales and Other State Non-Income Tax Liabilities

The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses on its condensed consolidated statements of operations and the liability is reflected in sales tax payable within other current liabilities as of September 30, 2016 and December 31, 2015, on its condensed consolidated balance sheets.

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the periods ended September 30, 2016 and 2015, the Company has calculated its effective tax rate based on year-to-date results (under ASC 740-270-30-18) as opposed to estimating its annual effective tax rate. The Company’s effective tax rate for the three and nine months ended September 30, 2016 was 5.3% and negative 44.4%, respectively, including the impact of discrete items. Excluding discrete items, the Company’s effective tax rate for the three and nine months ended September 30, 2016 was 5.0% and negative 43.3%, respectively. The effective tax rates are different than the statutory rates primarily due to the impact from amortization of indefinite-lived intangible assets for tax purposes, the partial non-deductibility of certain per diem expenses and international and state minimum taxes. The Company records valuation allowances to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment, including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support its reversal. As of September 30, 2016, the Company had approximately $0.9 million of unrecognized tax benefits included in other current liabilities and other long-term liabilities ($4.6 million, net of deferred taxes, which would affect the effective tax rate if recognized). During the nine months ended September 30, 2016, the Company had gross increases of $0.8 million to its current year unrecognized tax benefits related to federal and state tax issues. The tax years of 2004, 2005, 2008, and 2010 through 2015 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services to hospitals which are affiliated with certain members of the Company’s Board of Directors. Management believes services with related parties were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was $1.3 million and $4.0 million for the three and nine months ended September 30, 2016, respectively, and was $3.0 million and $10.1 million for the three and nine months ended September 30, 2015, respectively. Accounts receivable due from these hospitals at both September 30, 2016 and December 31, 2015 were approximately $0.6 million. In connection with the acquisition of MSN, the Company acquired a 68% ownership interest in InteliStaf of Oklahoma, LLC, a joint venture between the Company and a hospital system. The Company generated revenue providing staffing services to the hospital system of $3.1 million and $9.1 million for the three and nine months ended September 30, 2016, respectively, and was $2.6 million and $6.9 million for the three and nine months ended September 30, 2015, respectively. At September 30, 2016 and December 31, 2015, the Company had a receivable balance of $1.0 million and $1.4 million, respectively, and a payable balance of $0.2 million at the end of each period, relating to these staffing services. Subsequent to the Company's acquisition of Mediscan on October 30, 2015, Mediscan continued to operate at premises owned, in part, by the founding members of Mediscan. The Company paid $0.1 million and $0.3 million in rent expense for these premises for the three and nine months ended September 30, 2016, respectively.

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments, which amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. This update intends to reduce the diversity that has resulted from the lack of consistent principles on this topic by adding or clarifying guidance on eight cash flow issues, including: debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted. Entities must apply the guidance retrospectively to all periods presented but may apply it prospectively from the earliest date practicable if retrospective application would be impracticable. The Company is currently evaluating the effect ASU 2016-15 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. There are various methods of adoption for each aspect. The Company is currently evaluating the effect ASU 2016-09 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging: Contingent Put and Call Options in Debt Instruments, to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. Early adoption is permitted. The Company is currently evaluating the effect ASU 2016-06 will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is currently evaluating the effect ASU 2016-02 will have on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These standards are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact, if any, it will have on its consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2015 condensed consolidated balance sheet included herein was derived from the December 31, 2015 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K. Certain prior period amounts have been reclassified to conform to the current period presentation. See Note 12 - Segment Data.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, the valuation of accounts receivable, goodwill and intangible assets, other long-lived assets, share-based compensation, accruals for health, workers’ compensation and professional liability claims, valuation of deferred tax assets and the purchase price allocation, derivative liability, legal contingencies, future contingent considerations, income taxes and sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805), Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Prior to the issuance of the ASU, entities were required to retrospectively apply adjustments made to provisional amounts recognized in a business combination. The Company adopted this guidance in the first quarter of 2016, with no impact on its financial position and results of operations upon adoption. This new guidance may impact the Company for potential measurement adjustments related to its 2015 acquisition. See Note 3 - Acquisitions. In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40), Customers Accounting for Fees Paid in a Cloud Computing Arrangement, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The amendment provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license element, then the customer should account for the software license element arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The Company prospectively adopted this guidance in the first quarter of 2016, with no impact on its condensed consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs. This guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The Company adopted this guidance in the first quarter of 2016, and reclassified $0.5 million of the Company's net debt issuance costs to long-term debt and capital lease obligations in its condensed consolidated balance sheets as of September 30, 2016 and December 31, 2015. RECENT ACCOUNTING PRONOUNCEMENTS In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments, which amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. This update intends to reduce the diversity that has resulted from the lack of consistent principles on this topic by adding or clarifying guidance on eight cash flow issues, including: debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted. Entities must apply the guidance retrospectively to all periods presented but may apply it prospectively from the earliest date practicable if retrospective application would be impracticable. The Company is currently evaluating the effect ASU 2016-15 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. There are various methods of adoption for each aspect. The Company is currently evaluating the effect ASU 2016-09 will have on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging: Contingent Put and Call Options in Debt Instruments, to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. Early adoption is permitted. The Company is currently evaluating the effect ASU 2016-06 will have on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is currently evaluating the effect ASU 2016-02 will have on its consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These standards are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the new guidance to determine the impact, if any, it will have on its consolidated financial statements.

ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Schedule of unaudited pro forma financial information



	Nine Months Ended
	September 30, 2015
	(unaudited, amounts in thousands)

Revenue from services	$	603,495

Net income attributable to common shareholders	$	11,964

Net income per share attributable to common shareholders - Basic	$	0.38

Net income per share attributable to common shareholders - Diluted	$	0.37

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share

The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016			2015		2016			2015
	(amounts in thousands, except per share data)
Numerator:
Net income attributable to common shareholders - Basic	$	14,066		$	5,009	$	15,851		$	10,516
Interest on Convertible Notes	853			*		2,529			*
Gain on derivative liability	(7,105		)	*		(19,970		)	*
Net income (loss) attributable to common shareholders - Diluted	$	7,814		$	5,009	$	(1,590	)	$	10,516

Denominator:
Weighted average common shares - Basic	32,221			31,541		32,088			31,412
Effective of dilutive shares:
Share-based awards	513			627		606			636
Convertible Notes	3,521			—		3,521			—
Weighted average common shares - Diluted	36,255			32,168		36,215			32,048

Net income per share attributable to common shareholders - Basic	$	0.44		$	0.16	$	0.49		$	0.33

Net income (loss) per share attributable to common shareholders - Diluted	$	0.22		$	0.16	$	(0.04	)	$	0.33

Schedule of Potentially Dilutive Securities



	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2016	2015	2016	2015
	(amounts in thousands)

Convertible Notes and share-based awards	2	3,521	13	3,521

GOODWILL AND OTHER INTANGIBLES (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Acquired Intangible Assets

As of September 30, 2016 and December 31, 2015, the Company had the following acquired intangible assets:



	September 30, 2016						December 31, 2015
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	(amounts in thousands)
Intangible assets subject to amortization:
Databases	$	31,225	$	15,646	$	15,579	$	31,225	$	14,150	$	17,075
Customer relationships	41,212		22,848		18,364		47,204		20,734		26,470
Non-compete agreements	3,603		3,516		87		3,603		3,486		117
Trade names, definite-lived	3,200		269		2,931		3,200		49		3,151
	$	79,240	$	42,279	$	36,961	$	85,232	$	38,419	$	46,813

Intangible assets not subject to amortization:
Goodwill					$	77,376					$	95,096
Trade names					35,452						36,101
					$	112,828					$	131,197

Estimated Annual Amortization Expense

As of September 30, 2016, estimated annual amortization expense is as follows:



Through Year Ending December 31:	(amounts in thousands)
2016	$	1,040
2017	4,140
2018	4,055
2019	4,019
2020	3,914
Thereafter	19,793
	$	36,961

Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill by segment are as follows:



	Nurse And Allied Staffing			Physician Staffing			Other Human Capital Management Services			Total
	(amounts in thousands)
Balances as of December 31, 2015
Aggregate goodwill acquired	$	302,005		$	43,405		$	19,307		$	364,717
Sale of CCE	—			—			(9,889		)	(9,889		)
Accumulated impairment loss	(259,732		)	—			—			(259,732		)
Goodwill, net of impairment loss	42,273			43,405			9,418			95,096

Changes to aggregate goodwill in 2016
Impairment charges	—			(17,720		)	—			(17,720		)

Balances as of September 30, 2016
Aggregate goodwill acquired	302,005			43,405			19,307			364,717
Sale of CCE	—			—			(9,889		)	(9,889		)
Accumulated impairment loss	(259,732		)	(17,720		)	—			(277,452		)
Goodwill, net of impairment loss	$	42,273		$	25,685		$	9,418		$	77,376

DEBT (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Long-term Debt

At September 30, 2016 and December 31, 2015, long-term debt consists of the following:



	September 30, 2016						December 31, 2015
	Principal			Unamortized Discount and Debt Issuance Costs			Principal			Unamortized Discount and Debt Issuance Costs
	(amounts in thousands)
Term Loan, interest 2.77%	$	39,500		$	(388	)	$	—		$	—
Senior Secured Asset-Based, weighted average interest 2.41%	—			—			8,000			—
Second Lien Term Loan, interest 5.75%	—			—			30,000			(1,052		)
Convertible Notes, fixed rate interest of 8.00%	25,000			(5,005		)	25,000			(6,007		)
Convertible Notes derivative liability	13,367			—			33,337			—
Capital lease obligations	34			—			94			—
Total debt	77,901			(5,393		)	96,431			(7,059		)
Less current portion	(2,272		)	—			(8,071		)	—
Long-term debt	$	75,629		$	(5,393	)	$	88,360		$	(7,059	)



Level	Consolidated Net Leverage Ratio	Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee	Base Rate Loans	Commitment Fee
I	Less than 1.50:1.00	1.75%	0.75%	0.25%
II	Greater than or equal to 1.50:1.00 but less than 2.00:1.00	2.00%	1.00%	0.30%
III	Greater than or equal to 2.00:1.00 but less than 2.50:1.00	2.25%	1.25%	0.30%
IV	Greater than or equal to 2.50:1.00 but less than 3.00:1.00	2.50%	1.50%	0.35%
V	Greater than or equal to 3.00:1.00	2.75%	1.75%	0.40%

Aggregate scheduled maturities of debt

As of September 30, 2016, the aggregate scheduled maturities of debt are as follows:



	Term Loan		Convertible Notes		Capital Leases
	(amounts in thousands)
Through Years Ending December 31:
2016	$	500	$	—	$	11
2017	2,500		—		13
2018	3,000		—		8
2019	3,500		—		2
2020	4,000		25,000		—
Thereafter	26,000		—		—
Total	$	39,500	$	25,000	$	34

CONVERTIBLE NOTES DERIVATIVE LIABILITY (Tables)

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Inputs into Valuation Model

The inputs into the valuation model are as follows:



	September 30, 2016
Closing share price	$11.78
Conversion price	$7.10
Risk-free rate	0.91%
Expected volatility	40%
Dividend yield	—%
Expected life	3.75

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis

The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis as of September 30, 2016 and December 31, 2015:

Fair Value Measurements



	September 30, 2016		December 31, 2015
Financial Liabilities:	(amounts in thousands)
(Level 1)
Deferred compensation	$	1,435	$	1,412
(Level 3)
Convertible Notes derivative liability	$	13,367	$	33,337
Contingent purchase price liabilities	$	4,196	$	3,686

Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3

The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy:



	Contingent Purchase			Convertible Notes
	Price Liabilities (a)			Derivative Liability
	(amounts in thousands)
December 31, 2015	$	3,686		$	33,337
Payments	(17		)	—
Accretion expense	287			—
Valuation gain for the period	—			(16,436		)
March 31, 2016	3,956			16,901
Accretion expense	183			—
Valuation loss for the period	—			3,571
June 30, 2016	4,139			20,472
Payments	(135		)	—
Accretion expense	192			—
Valuation gain for the period	—			(7,105		)
September 30, 2016	$	4,196		$	13,367

_______________

(a)

Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value

The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value:



	September 30, 2016				December 31, 2015
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Financial Liabilities:			(amounts in thousands)
(Level 2)
Second Lien Term Loan, net	$	—	$	—	$	28,948	$	30,600
Term Loan, net	$	39,112	$	39,500	$	—	$	—
Convertible Notes, net	$	19,995	$	28,750	$	18,993	$	23,250
Senior Secured Asset-Based Loan	$	—	$	—	$	8,000	$	8,000

STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Summary of Restricted Stock Activity

The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the nine months ended September 30, 2016:



	Restricted Stock Awards				Performance Stock Awards
	Number of Shares		Weighted Average Grant Date Fair Value		Number of Target Shares		Weighted Average Grant Date Fair Value
Unvested restricted stock awards, January 1, 2016	586,488		$	7.82	234,138		$	9.81
Granted	246,020		$	12.01	202,442		$	11.63
Vested	(272,597	)	$	7.06	—		$	—
Forfeited	(14,000	)	$	10.93	(10,667	)	$	11.77
Unvested restricted stock awards, September 30, 2016	545,911		$	10.01	425,913		$	10.62

SEGMENT DATA (Tables)

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Information on Operating Segments and Reconciliation to Loss From Operations

Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows:



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2016			2015		2016			2015
	(amounts in thousands)
Revenues:
Nurse and Allied Staffing	$	186,623		$	157,338	$	527,436		$	459,127
Physician Staffing	25,090			30,959		73,470			88,100
Other Human Capital Management Services	3,275			7,395		10,108			27,046
	$	214,988		$	195,692	$	611,014		$	574,273

Contribution income: (a)
Nurse and Allied Staffing (b)	$	19,472		$	16,560	$	53,877		$	40,283
Physician Staffing	2,400			3,197		6,003			7,541
Other Human Capital Management Services	(154		)	372		(196		)	1,721
	21,718			20,129		59,684			49,545

Unallocated corporate overhead (b)	9,449			8,419		29,608			24,714
Depreciation	995			953		3,059			2,902
Amortization	1,097			982		3,910			2,947
Loss on sale of business	—			2,184		—			2,184
Acquisition and integration costs	—			584		—			742
Acquisition-related contingent consideration	237			—		707			—
Restructuring costs	611			140		611			1,147
Impairment charges	—			—		24,311			—
Income (loss) from operations	$	9,329		$	6,867	$	(2,522	)	$	14,909

_______________

(a)


(b)	For the three and nine months ended September 30, 2015, $0.3 million and $0.9 million, respectively, of expenses were reclassified from Nurse and Allied Staffing to unallocated corporate overhead to conform to the current period presentation.

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments

Future minimum lease payments, as of September 30, 2016, associated with these agreements with terms of one year or more are as follows:



Through Year Ending December 31:	(amounts in thousands)
2016	$	1,900
2017	6,857
2018	5,851
2019	4,349
2020	3,834
Thereafter	16,605
	$	39,396

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Long-term Debt and Capital Lease Obligations [Member] \| Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of debt issuance costs	$ 0.5	$ 0.5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring liability	$ 700		$ 700		$ 400
Restructuring charge	611	$ 140	611	$ 1,147
Payment for restructuring liability			300
Post-employment Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring liability	300		300		100
Restructuring charge	400		400
Payment for restructuring liability	100		200
Exit Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring liability	400		400		$ 300
Restructuring charge	$ 200		200
Payment for restructuring liability			$ 100

ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands				9 Months Ended		21 Months Ended
ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands	Apr. 01, 2016	Oct. 30, 2015	Jun. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Business Acquisition [Line Items]
Cash purchase price paid at closing				$ 2,155	$ 123
Acquisition-related contingent consideration				662	$ 0
Mediscan [Member]
Business Acquisition [Line Items]
Cash purchase price paid at closing		$ 29,900
Cash consideration negotiated		28,000
Fair value of shares		$ 4,700
Fair value of shares (in shares)		349,871
Contingent consideration, range of outcomes, high		$ 7,000
Contingent purchase price liabilities				$ 4,200
Medical Staffing Network [Member]
Business Acquisition [Line Items]
Contingent purchase price liabilities			$ 2,500
Period of deferred consideration (in months)			21 months
Additional exit liabilities						$ 400
Acquisition-related contingent consideration	$ (2,100)

ACQUISITIONS - Schedule of Pro-forma Information (Details) - Mediscan [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($) $ / shares
Business Acquisition [Line Items]
Revenue from services \| $	$ 603,495
Net income attributable to common shareholders \| $	$ 11,964
Net income per share attributable to common shareholders - Basic (in dollars per share) \| $ / shares	$ 0.38
Net income per share attributable to common shareholders - Diluted (in dollars per share) \| $ / shares	$ 0.37

DISPOSAL (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
DISPOSAL (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business				$ 500	$ 7,500
Loss on sale of business		$ 0	$ 2,184	$ 0	$ 2,184
Cross Country Education, LLC [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business	$ 8,000
Contingent liability	$ 500
Earn-out held in escrow, term (in months)	12 months
Performance related earn-out						$ 500

COMPREHENSIVE INCOME (LOSS) (Details) - USD ($)	3 Months Ended		9 Months Ended
COMPREHENSIVE INCOME (LOSS) (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Equity [Abstract]
Loss (gain) of currency fluctuations	$ 1,200,000		$ 1,200,000		$ 1,200,000
Income tax impact related to foreign currency translation adjustments	$ 0	$ 0	$ 0	$ 0

EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Net income attributable to common shareholders - Basic	$ 14,066	$ 5,009	$ 15,851	$ 10,516
Interest on Convertible Notes	853		2,529
Gain on derivative liability	(7,105)		(19,970)
Net income (loss) attributable to common shareholders - Diluted	$ 7,814	$ 5,009	$ (1,590)	$ 10,516
Weighted average common shares - Basic	32,221	31,541	32,088	31,412
Effective of dilutive shares:
Share-based awards (shares)	513	627	606	636
Convertible Notes (shares)	3,521	0	3,521	0
Diluted weighted average common shares outstanding (shares)	36,255	32,168	36,215	32,048
Net income per share attributable to common shareholders - Basic
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ 0.44	$ 0.16	$ 0.49	$ 0.33
Net (loss) income per share attributable to common shareholders - Diluted
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.22	$ 0.16	$ (0.04)	$ 0.33

EARNINGS PER SHARE - Antildilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Convertible Notes and Share-based Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2	3,521	13	3,521

GOODWILL AND OTHER INTANGIBLES - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 79,240	$ 85,232
Accumulated Amortization	42,279	38,419
Intangible assets subject to amortization, net carrying amount	36,961	46,813
Goodwill	77,376	95,096
Trade names	35,452	36,101
Intangible assets not subject to amortization, net	112,828	131,197
Database [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	31,225	31,225
Accumulated Amortization	15,646	14,150
Intangible assets subject to amortization, net carrying amount	15,579	17,075
Customer Relationships [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	41,212	47,204
Accumulated Amortization	22,848	20,734
Intangible assets subject to amortization, net carrying amount	18,364	26,470
Noncompete Agreements [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,603	3,603
Accumulated Amortization	3,516	3,486
Intangible assets subject to amortization, net carrying amount	87	117
Trade names, definite lived [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,200	3,200
Accumulated Amortization	269	49
Intangible assets subject to amortization, net carrying amount	$ 2,931	$ 3,151

GOODWILL AND OTHER INTANGIBLES - Impairment Testing (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)
Finite-Lived Intangible Assets [Line Items]
Non-cash impairment charges	$ 0		$ 0	$ 24,311	$ 0
Impairment related to goodwill				17,720
Physician Staffing [Member]
Finite-Lived Intangible Assets [Line Items]
Non-cash impairment charges		$ 24,300		24,300
Impairment related to goodwill		$ 17,700		17,720
Physician Staffing [Member] \| Income Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discount rate percentage		11.50%
Terminal value growth rate percentage		3.00%
Physician Staffing [Member] \| Market Approach Valuation Technique [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Total Enterprise Value/EBITDA ratio		7.5
Physician Staffing [Member] \| Market Approach Valuation Technique [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Total Enterprise Value/EBITDA ratio		8.5
Physician Staffing [Member] \| Income and Market Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discrete forecast period (in years)		10 years
Physician Staffing [Member] \| Income and Market Approach Valuation Technique [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted percentage applied		50.00%
Physician Staffing [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment related to finite lived assets		$ 6,000		6,000
Physician Staffing [Member] \| Customer Relationships [Member] \| Income Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Discount rate percentage		13.50%
Physician Staffing [Member] \| Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment related to indefinite lived assets		$ 600		$ 600

GOODWILL AND OTHER INTANGIBLES - Annual Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 1,040
2017	4,140
2018	4,055
2019	4,019
2020	3,914
Thereafter	19,793
Intangible assets subject to amortization, net carrying amount	$ 36,961	$ 46,813

GOODWILL AND OTHER INTANGIBLES - Goodwill Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Goodwill, beginning		$ 95,096
Aggregate goodwill acquired		364,717	$ 364,717
Sale of CCE		(9,889)	(9,889)
Accumulated impairment loss		(277,452)	(259,732)
Impairment charges		(17,720)
Goodwill, ending		77,376	95,096
Nurse And Allied Staffing [Member]
Goodwill [Roll Forward]
Goodwill, beginning		42,273
Aggregate goodwill acquired		302,005	302,005
Sale of CCE		0	0
Accumulated impairment loss		(259,732)	(259,732)
Impairment charges		0
Goodwill, ending		42,273	42,273
Physician Staffing [Member]
Goodwill [Roll Forward]
Goodwill, beginning		43,405
Aggregate goodwill acquired		43,405	43,405
Sale of CCE		0	0
Accumulated impairment loss		(17,720)	0
Impairment charges	$ (17,700)	(17,720)
Goodwill, ending		25,685	43,405
Other Human Capital Management Services [Member]
Goodwill [Roll Forward]
Goodwill, beginning		9,418
Aggregate goodwill acquired		19,307	19,307
Sale of CCE		(9,889)	(9,889)
Accumulated impairment loss		0	0
Impairment charges		0
Goodwill, ending		$ 9,418	$ 9,418

DEBT - Long- Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Capital lease obligations	$ 34	$ 94
Total debt	77,901	96,431
Less current portion	(2,272)	(8,071)
Long-term Debt and Capital Lease Obligations	75,629	88,360
Unamortized Discount and Debt Issuance Costs	(5,393)	(7,059)
Unamortized Discount and Debt Issuance Costs, Noncurrent	(5,393)	(7,059)
Revolving Credit Facility [Member] \| Senior Secured Asset-Backed [Member]
Debt Instrument [Line Items]
Debt	0	8,000
Unamortized Discount and Debt Issuance Costs	0	$ 0
Weighted average interest rate		2.41%
Senior Debt [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Debt	39,500	$ 0
Unamortized Discount and Debt Issuance Costs	$ (388)	0
Interest Rate	2.77%
Subordinated Debt [Member] \| Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt	$ 0	30,000
Unamortized Discount and Debt Issuance Costs	0	$ (1,052)
Interest Rate		5.75%
Convertible Notes [Member] \| 8% Convertible Notes [Member]
Debt Instrument [Line Items]
Debt	25,000	$ 25,000
Unamortized Discount and Debt Issuance Costs	$ (5,005)	$ (6,007)
Interest Rate	8.00%	8.00%
Convertible Notes [Member] \| Convertible Note Derivative Liability [Member]
Debt Instrument [Line Items]
Debt	$ 13,367	$ 33,337
Unamortized Discount and Debt Issuance Costs	$ 0	$ 0

DEBT - Debt Maturities (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Capital Lease Obligations [Abstract]
2016	$ 11
2017	13
2018	8
2019	2
2020	0
Thereafter	0
Total	34
Term Loan [Member]
Long-term Debt, Fiscal Year Maturity [Abstract]
2016	500
2017	2,500
2018	3,000
2019	3,500
2020	4,000
Thereafter	26,000
Total	39,500
Convertible Notes [Member]
Long-term Debt, Fiscal Year Maturity [Abstract]
2016	0
2017	0
2018	0
2019	0
2020	25,000
Thereafter	0
Total	$ 25,000

DEBT - Narrative (Details)		3 Months Ended			9 Months Ended		12 Months Ended
DEBT - Narrative (Details)	Jun. 22, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) financial_covenant	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Debt Instrument [Line Items]
Prepayment penalty	$ 600,000
Loss on early extinguishment of debt		$ 0		$ 0	$ 1,568,000	$ 0
Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Loss on early extinguishment of debt			$ 1,600,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Interest rate increase (decrease) (percent)					2.00%
Quarterly commitment fee on the average daily unused portion (percent)					0.30%
Number of financial covenants \| financial_covenant					2
Credit Agreement [Member] \| Senior Debt [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 40,000,000.0
Percentage of principal payment for first four installments	1.25%
Percentage of principal payment for next eight installments	1.875%
Percentage of principal payment for remaining installments	2.50%
Credit Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Consolidated Fixed Charge Coverage Ratio		1.50			1.50
Credit Agreement [Member] \| LIBOR [Member] \| Senior Debt [Member]
Debt Instrument [Line Items]
Interest margin					2.25%
Revolving Credit Facility [Member] \| First Lien Loan Agreement [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity							$ 85,000,000.0
Subfacility loans percentage up to aggregate revolver commitments (percent)							10.00%
Line of credit, subfacility for standby letters of credit							$ 35,000,000.0
Letters of credit rolled and issued under new facility	$ 23,100,000
Revolving Credit Facility [Member] \| Second Lien Term Loan [Member] \| Subordinated Debt [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity							$ 30,000,000.0
Line of credit facility, term (in years)							5 years
Revolving Credit Facility [Member] \| Second Lien Term Loan [Member] \| Period July 1, 2015 through June 30, 2016 [Member] \| Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed							103.00%
Revolving Credit Facility [Member] \| Second Lien Term Loan [Member] \| Period July 1, 2016 through June 30, 2017 [Member] \| Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed							102.00%
Revolving Credit Facility [Member] \| Second Lien Term Loan [Member] \| After June 30, 2017 [Member] \| Subordinated Debt [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed							100.00%
Revolving Credit Facility [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	100,000,000.0
Line of credit, subfacility for standby letters of credit	35,000,000.0
Sub facility for swingline loans	15,000,000.0
Additional capacity	$ 50,000,000.0
Letters of credit outstanding		$ 22,200,000			$ 22,200,000
Line of credit outstanding		$ 77,800,000			$ 77,800,000
Revolving Credit Facility [Member] \| Credit Agreement [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Interest margin					2.25%
Fiscal Quarters Ending September 30, 2016 through June 30, 2017 [Member] \| Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3.50			3.50
Fiscal Quarters Ending September 30, 2017 through June 30, 2018 [Member] \| Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3.25			3.25
Each Fiscal Quarter Ending Thereafter [Member] \| Credit Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Consolidated Net Leverage Ratio		3.00			3.00

DEBT - Private Placement of Convertible Notes Narrative (Details) - Convertible Senior Notes [Member]	9 Months Ended
	Sep. 30, 2016 instrument d $ / shares shares
Debt Instrument [Line Items]
Common stock, par value (in usd per share)	$ 0.0001
Debt conversion price (in usd per share)	$ 7.10
Debt instrument, convertible, number of equity instruments \| instrument	3,521,126
Debt Instrument, convertible, threshold period following issuance date (in years)	3 years
Debt instrument, convertible, threshold percentage of stock price trigger	125.00%
Debt instrument, convertible, threshold trading days \| d	20
Debt instrument, convertible, threshold consecutive trading days	30 days
Debt Instrument, Convertible, Number of Shares Not to Be Exceeded, Aggregate Number of Shares Previously Converted \| shares	6,420,028
Interest rate (percent)	8.00%
Debt instrument, interest, percent paid in kind, maximum	4.00%
Convertible debt redeemed after permissible date, redemption premium, percent of principal	15.00%
Convertible debt redeemed before permissible date, redemption premium, percent of principal	115.00%
Treasury Rate [Member]
Debt Instrument [Line Items]
Convertible debt, basis spread on discount rate on redemption, percentage	0.50%

CONVERTIBLE NOTES DERIVATIVE LIABILITY (Details)	9 Months Ended
CONVERTIBLE NOTES DERIVATIVE LIABILITY (Details)	Sep. 30, 2016 $ / shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Closing share price (in usd per share)	$ 11.78
Conversion price (in usd per share)	$ 7.10
Risk-free rate (as a percentage)	0.91%
Expected volatility (as a percentage)	40.00%
Dividend yield (as a percentage)	0.00%
Expected life (in years)	3 years 9 months

CONVERTIBLE NOTES DERIVATIVE LIABILITY - Narrative (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase or decrease in valuation of embedded derivative liability due to dollar change in stock price	$ 3.3
Increase or decrease in valuation of embedded derivative liability due to percentage change in interest rates	$ 0.8
Embedded Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in stock price (in usd per share) \| $ / shares	$ 1
Change in interest rates (as a percentage)	1.00%

FAIR VALUE MEASUREMENTS - Narrative (Details)	9 Months Ended
FAIR VALUE MEASUREMENTS - Narrative (Details)	Sep. 30, 2016
Minimum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided (in days)	15 days
Maximum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided (in days)	60 days

FAIR VALUE MEASUREMENTS - Estimated Fair values Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Inputs, Level 1 [Member] \| Deferred compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	$ 1,435	$ 1,412
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase price liabilities	4,196	3,686
Fair Value, Inputs, Level 3 [Member] \| Convertible Notes, Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible Notes derivative liability	$ 13,367	$ 33,337

FAIR VALUE MEASUREMENTS - Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016
Contingent Consideration Liability [Member]
Convertible Note Derivative Liability
Beginning balance	$ 4,139	$ 3,956	$ 3,686
Payments	(135)		(17)
Accretion expense	192	183	287
Valuation gain for the period	0	0	0
Ending balance	4,196	4,139	3,956
Derivative Financial Instruments, Liabilities [Member]
Convertible Note Derivative Liability
Beginning balance	20,472	16,901	33,337
Payments	0		0
Accretion expense	0	0	0
Valuation gain for the period	(7,105)	3,571	(16,436)
Ending balance	$ 13,367	$ 20,472	$ 16,901

FAIR VALUE MEASUREMENTS - Financial Instrument that were not Measured at Fair Value (Details) - Fair Value, Inputs, Level 2 [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Second Lien Term Loan, Net [Member] \| Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	$ 0	$ 28,948
Second Lien Term Loan, Net [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	0	30,600
Term Loan, Net [Member] \| Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	39,112	0
Term Loan, Net [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	39,500	0
Convertible Notes, Net [Member] \| Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	19,995	18,993
Convertible Notes, Net [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	28,750	23,250
Senior Secured Asset-Based Loan [Member] \| Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	0	8,000
Senior Secured Asset-Based Loan [Member] \| Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	$ 0	$ 8,000

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)	3 Months Ended			9 Months Ended
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares left remaining to repurchase under the plan (up to)	942,443			942,443
Stock repurchase program, authorized amount (up to)	$ 2,500,000			$ 2,500,000
Number of shares of common stock outstanding	32,238,463			32,238,463
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 800,000		$ 600,000	$ 2,600,000	$ 1,800,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				246,020
Vested in period, net (in shares)	9,742		10,330	225,107	190,631
Restricted Stock [Member] \| Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				246,020
Performance Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				202,442
Performance Stock [Member] \| Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				202,442
Level of performance attained and approved (percent)		100.00%
Shares issued in period		148,178

STOCKHOLDERS' EQUITY - Summary of Restricted Stock and Performance Shares (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Restricted Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) \| shares	586,488
Granted (in shares) \| shares	246,020
Vested (in shares) \| shares	(272,597)
Forfeited (in shares) \| shares	(14,000)
Unvested restricted stock awards, Ending balance (in shares) \| shares	545,911
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) \| $ / shares	$ 7.82
Granted (in dollars per share) \| $ / shares	12.01
Vested (in dollars per share) \| $ / shares	7.06
Forfeited (in dollars per share) \| $ / shares	10.93
Unvested restricted stock awards, Ending balance (in dollars per share) \| $ / shares	$ 10.01
Performance Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) \| shares	234,138
Granted (in shares) \| shares	202,442
Vested (in shares) \| shares	0
Forfeited (in shares) \| shares	(10,667)
Unvested restricted stock awards, Ending balance (in shares) \| shares	425,913
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) \| $ / shares	$ 9.81
Granted (in dollars per share) \| $ / shares	11.63
Vested (in dollars per share) \| $ / shares	0.00
Forfeited (in dollars per share) \| $ / shares	11.77
Unvested restricted stock awards, Ending balance (in dollars per share) \| $ / shares	$ 10.62

SEGMENT DATA - Narrative (Details)	9 Months Ended
SEGMENT DATA - Narrative (Details)	Sep. 30, 2016 segment
Segment Reporting [Abstract]
Number of operating segments	3

SEGMENT DATA - Information on Operating Segments and Reconciliation to Loss From Operations (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	$ 214,988		$ 195,692	$ 611,014	$ 574,273
Contribution income	21,718		20,129	59,684	49,545
Unallocated corporate overhead	9,449		8,419	29,608	24,714
Depreciation	995		953	3,059	2,902
Amortization	1,097		982	3,910	2,947
Loss on sale of business	0		2,184	0	2,184
Acquisition and integration costs	0		584	0	742
Acquisition-related contingent consideration	237		0	707	0
Restructuring costs	611		140	611	1,147
Impairment charges	0		0	24,311	0
Income (loss) from operations	9,329		6,867	(2,522)	14,909
Nurse and allied staffing [Member] \| Scenario, Adjustment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Contribution income			(300)		(900)
Physician staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Impairment charges		$ 24,300		24,300
Operating Segments [Member] \| Nurse and allied staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	186,623		157,338	527,436	459,127
Contribution income	19,472		16,560	53,877	40,283
Operating Segments [Member] \| Physician staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	25,090		30,959	73,470	88,100
Contribution income	2,400		3,197	6,003	7,541
Operating Segments [Member] \| Other human capital management services [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	3,275		7,395	10,108	27,046
Contribution income	$ (154)		$ 372	$ (196)	$ 1,721

COMMITMENTS AND CONTINGENIES (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	$ 1,900
2017	6,857
2018	5,851
2019	4,349
2020	3,834
Thereafter	16,605
Total future minimum lease payments	$ 39,396

INCOME TAXES (Details) $ in Millions	3 Months Ended	9 Months Ended
INCOME TAXES (Details) $ in Millions	Sep. 30, 2016 USD ($)	Sep. 30, 2016 USD ($)
Income Tax Disclosure [Abstract]
Effective tax rate (percentage)	5.30%	(44.40%)
Effective income tax rate continuing operations excluding discrete items (percentage)	5.00%	(43.30%)
Unrecognized tax benefits	$ 0.9	$ 0.9
Unrecognized tax benefits that would impact effective tax rate	$ 4.6	4.6
Gross increase to current year unrecognized tax benefits related to federal and state tax issues		$ 0.8
Income tax examination years subject to examination		2004, 2005, 2008, and 2010 through 2015

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Revenue from related parties	$ 1.3	$ 3.0	$ 4.0	$ 10.1
Accounts receivable from related parties	0.6		0.6		$ 0.6
InteliStaf [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$ 3.1	$ 2.6	$ 9.1	$ 6.9
Joint venture, percent ownership	68.00%		68.00%
Receivable balance with joint venture	$ 1.0		$ 1.0		1.4
Payable balance with joint venture	0.2		0.2		$ 0.2
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Rent expense	$ 0.1		$ 0.3

DEBT - Consolidated Net Leverage Ratio (Details) - Credit Agreement [Member]	9 Months Ended
	Sep. 30, 2016
Covenant Term 1 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.25%
Covenant Term 1 [Member] \| Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] \| LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] \| Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 1 [Member] \| Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	0.75%
Covenant Term 1 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	1.50
Covenant Term 2 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Covenant Term 2 [Member] \| Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] \| LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] \| Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.00%
Covenant Term 2 [Member] \| Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.00%
Covenant Term 2 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	1.50
Covenant Term 2 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.00
Covenant Term 3 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Covenant Term 3 [Member] \| Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] \| LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] \| Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%
Covenant Term 3 [Member] \| Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.25%
Covenant Term 3 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.00
Covenant Term 3 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.50
Covenant Term 4 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.35%
Covenant Term 4 [Member] \| Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] \| LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] \| Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.50%
Covenant Term 4 [Member] \| Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.50%
Covenant Term 4 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	2.50
Covenant Term 4 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	3.00
Covenant Term 5 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.40%
Covenant Term 5 [Member] \| Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] \| LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] \| Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin	2.75%
Covenant Term 5 [Member] \| Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.75%
Covenant Term 5 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio	3.00